Roche is buying PathAI for $750 million upfront — it’s a total deal worth up to $1.05 billion once milestones are included. The deal closes in the second half of 2026.
What does Roche actually get? PathAI’s core product is its Image Management System, a software platform that ties together analysis and workflow tools inside the digital pathology lab. Roche plans to scale it globally. PathAI also brings AI-driven clinical trial support and translational research capabilities: pairing with Roche’s existing companion diagnostics know-how.
The milestone structure tells the real story. Roche is paying $750 million now and betting up to $300 million more on PathAI’s future performance. PathAI’s biggest regulatory win to date came in early December, when the FDA qualified its AIM-NASH tool, a cloud-based AI system for scoring liver biopsies in MASH clinical trials. AIM-NASH covers fat infiltration, inflammation, and scarring, and it was the first FDA qualification of its kind. One qualification doesn’t justify $1 billion alone; the IMS platform is clearly the primary driver of the price.
Roche and PathAI have been partners since 2021, with their relationship expanding in 2024 to include AI-enabled companion diagnostic algorithms. Matt Sause, CEO of Roche Diagnostics, said combining PathAI’s tools with Roche’s oncology platforms should improve physician insights and patient outcomes.
PathAI merges into Roche Diagnostics once the deal closes in H2 2026.
Diana Kowalski